UNSPSC 51171638: Methylnaltrexone

This classification denotes an opiate antagonist with the moleculat formula C21H26NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0RK7M7IABE. European Medicines Agency schedules Methylnaltrexone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33963. The term METHYLNALTREXONE is a European Medicines Agency European Public Assessment Report System designation. As of Q4 2014, METHYLNALTREXONE remains the US FDA Preferred Term for this commodity.

Methylnaltrexone bears US NLM identifiers UMLS ID C0066411 and NCI Concept Code C48403. SMILES: C[N+]1(CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6.

UNSPSC 51171638 Methylnaltrexone, a Commodity code, shows limited recent state and local procurement activity directly aligned with the pharmaceutical product itself. The three most recent opportunities tagged to this code span offender drug testing, therapeutic pharmacy direct-to-manufacturer contracting, and generic multi-source pharmaceutical cooperative purchasing — none of which explicitly names methylnaltrexone as a line item or required therapeutic. The mismatch suggests that state and local procurement offices are using this code broadly to flag pharmaceutical-adjacent services and products rather than targeting the specific opioid-antagonist medication. Collin County Community Supervision and Corrections Department (Texas) solicited offender specimen collection and drug testing services under RFP 2026-327, due July 23, 2026, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026 — this opportunity centers on testing infrastructure and staffing, not medications. The Texas Health and Human Services Commission issued RFI HHS0017013 on direct-to-manufacturer prescription programs to explore state capacity to bypass traditional pharmacy benefit managers; this remains exploratory market intelligence gathering with no formal award value or binding timeline. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, effective July 1, 2026, with a two-year contract term — this cooperative vehicle serves state and local government facilities across multiple states including Oregon but does not itemize methylnaltrexone specifically.

Geographic activity is concentrated in Texas (two of three recent opportunities) and the Upper Midwest cooperative region (Minnesota and participating states). The code shows little concrete evidence of state and local governments actively procuring methylnaltrexone as a named pharmaceutical product in recent months. Firms considering pursuit under this code should clarify whether methylnaltrexone demand exists within existing pain-management, addiction-treatment, or pharmaceutical-supply contracts at the target agency level rather than rely on the code signal alone.